Isomorphic Labs Secures $600M to Advance AI Drug Design

Isomorphic Labs, a spinout from DeepMind, has raised $600 million in its first external funding round. The round was led by Thrive Capital, with participation from Google Ventures and Alphabet. This funding aims to accelerate the development of Isomorphic Labs' AI drug design engine and advance its drug candidates to clinical trials by the end of the year.

The company, headquartered in London with an office in Lausanne, Switzerland, is focused on reducing the time required to discover new medicines. It leverages DeepMind's AlphaFold technology to predict protein interactions with other molecules, applying this to a broader range of biological molecules. Isomorphic Labs has partnered with pharmaceutical giants like Eli Lilly and Novartis and is primarily focused on oncology and immunology.

Demis Hassabis, founder and CEO of Isomorphic Labs, stated that the funding will enhance their AI research and development efforts and expand their team. The company has been on a rapid growth trajectory since its inception in 2021, having quadrupled its R&D spending in 2023.